The objective of the present study was to formulate and evaluate Effervescent Floating Tablet of Fluoxetine for the treatment of antidepressant agent. Tablets were prepared by direct compression using directly compressible polymers such as HPMC K4M, and Carbopol 934 were evaluated for drug-excipient compatibility, density, buoyancy test, swelling study, drug content and In-Vitro release profile. Sodium bicarbonate and citric acid were used producing effervescent base for buoyancy of tablets. Analysis of drug release from tablet indicates drug release by zero order, first order rate kinetics. No significant change was observed in physical appearance, drug content, floatability or in-vitro dissolution pattern after storage at 45 0 C/75 0 C RH for three months.
INTRODUCTION
Oral drug administration still remains the route of choice for the majority of clinical applications some drug have ideal characteristics for good absorption to occur desirable for optimizing the therapeutic benefit of the drug 1 . Oral delivery of drugs is by far the most preferable route of drug delivery due to the ease of administration, patient compliance and flexibility in formulation 2 . Attempts have been made to be 8-10 hr. From mouth to colon, is relatively brief with considerable fluctuation. One of the important determinants of G.I transit is the residence time in the stomach. The oral controlled delivery of drugs having "absorption window" continually releasing the drug prior to absorption window for prolonged period of time, thus ensuring optimal bioavailability 3 . A floating dosage unit is useful for drugs acting locally in the proximal gastrointestinal tract. These systems are also useful for drugs that are poorly soluble or unstable in intestinal fluids. Floating tablets and Floating capsules are common examples of floating system 4, 5 .
Effervescent Floating Drug Delivery System:
A gastro retentive dosage form will release the drug over an extended period in the stomach and upper gastrointestinal tract (GIT) thus enhancing the opportunity for absorption.
Various approaches have been proposed to control the gastric residence of drug delivery system in the upper part of the GIT including floating drug delivery system. High density DDS, bioadhesive systems, swelling and expanding DDS, modified shape systems and other delayed gastric devices 5, 6 . FDDS is suitable for drugs with an absorption window in the stomach or the upper small intestine, for drugs which act locally in the stomach and for drugs that are poorly soluble or unstable in the intestinal fluid DDS or hydro dynamically balanced systems have a bulk density lower than gastric fluid and thus remain buoyant in the stomach without affecting the gastric emptying rate for a prolonged period of time. Based on the mechanism of buoyancy, two distinctly different technologies, i.e. noneffervescent and effervescent systems, have been used in the development of FDDS 6,7,8 .
The effervescent system uses matrices prepared with swellable polymers and effervescent components e.g. sodium bicarbonate and citric acid or stearic acid. In noneffervescent FDDS, the drug mixes with a gel forming hydrocolloid, which swells in contact with gastric fluid after oral administration to maintain a relatively stable shape and a bulk density of less than unity within the outer gelatinous barrier 9 . Preformulation testing is the first step in the rational development of dosage forms of a drug. It can be defined as an investigation of physical and chemical properties of drug substance, alone and when combined with excipients. The overall objective of preformulation testing is to generate information useful to the formulator in developing stable and bioavailable dosage forms, which can be massproduced 10, 11 .
Identification Tests a) Organoleptic Properties:
The sample of Fluoxetine was studied for organoleptic characteristics such as colour, odour and appearance 10, 11 .
b) Melting Point:
Melting point of Fluoxetine was determined by taking a small amount of sample in a capillary tube closed at one end and placed in melting point apparatus. The melting point was noted in triplicate and average value was noted 10, 11 .
c) IR Spectroscopy
The FT-IR spectrum of the obtained sample of drug was compared with the standard FT-IR spectra of the pure drug.
d) Solubility analysis:
Preformulation solubility analysis was done to select a suitable solvent system to dissolve the drug and also to test its solubility in the dissolution medium which was to be used.
e) Differential Scanning Calorimetry:
The powdered sample (3 mg) was hermetically sealed in aluminium pans and heated at a constant rate 10 0 C/min, over a temperature range of 30-300 0 C with nitrogen flow rate of 30ml/min. Thermograms of the samples were obtained using differential scanning Calorimetry (DSC-60, Shimadzu, Japan). Thermal analysis data were recorded with Shimadzu software programs. Indian standard was to calibrate the DSC temperature and enthalpy scale.
Compatibility studies a) IR Spectroscopy
Compatibility study was carried out by using Fourier Transform Infrared Spectrophotometer (BRUCKER). IR study was carried on pure drug. Physical mixture of drug and excipients were prepared and samples kept for 1 month at 40 0 C. The infrared absorption spectrum of Fluoxetine and physical mixture of drug and excipient was recorded using diamond disc 12, 13 .
b) Preparation of 0.1 N HCL 8.5 ml of concentrated HCL was taken and diluted with distilled water up to 1000 ml.
c) Preparation of Standard Calibration curve of Fluoxetine
The UV spectrum of Fluoxetine was obtained by using UV (Shimadzu UV -1800, Japan). Accurately weighed 10 mg of the drug was dissolved in sufficient quantity of 0.1 N HCl and volume made up to 10 ml. The stock solution was diluted to obtain a concentration of 100 µg/ml. 1 ml of aliquot was withdrawn and volume was made up to 10 ml using 0.1 N HCl to obtain the concentration of 10 µg/ml. The resultant solution was scanned from 400 to 200 nm and the spectrum was recorded to obtain the value of maximum Wavelength in respective solvents 10, 11 .
Formulation and Preparation of Effervescent Floating of Fluoxetine tablet by direct compression
Weight all the ingredient accurately fist add polymer HPMC K4M in mortar then Carbopol 934 & Sodium bicarbonate mix it well for 10 min then add drug , magnesium stearate & lactose blend for 10 min at the last magnesium stearate 1% add mix all ingredient homogenously to form a tablet mix for direct compression 14 .
Evaluation of powder
The flow properties of granules (before compression) were characterized in terms of angle of repose, tapped density, bulk density, Carr's index and Hausner's ratio 3,4,15 . Fluoxetine  75  75  75  75  75  75  75  75  75  HPMC K4M  50  50  50  60  60  60  70  70  70  Carbopol 934  10  15  20  10  15  20  10  15  20  Sodium  Bicarbonate  30  30  30  30  30  30  30  30  30   Citric acid  10  10  10  10  10  10  10  10  10  Mg Stearate  3  3  3  3  3  3  3  3  3  Lactose  47  42  37  37  32  27  27  22  17  Total Weight  225  225  225  225  225  225  225  225  225 Determination of Swelling Index:
Table No 2: Formulation Chart of Effervescent Floating Tablet of Fluoxetine

Ingredients Formulation code
The swelling properties of matrices containing drug were determined by placing tablet matrices in the dissolution test apparatus in 900 ml 0.1 N HCl at 37 ± 0.5 0 C. The tablets were removed periodically from the dissolution medium and, after removing free water, the weight gain was measured. The swelling characteristics were expressed in terms of the percentage water uptake (WU %) according to the equation 5 .
Determination of Floating capacity:
Three individual tablets from each formulation were put in an individual flask containing 400ml of 0.1 N HCl solutions. 
In-vitro Disintegration Time:
Disintegration time was determined using USP disintegration apparatus with distilled water. The volume of medium was 900 ml and temperature was 37 ± 0.2 0 C. The time in minutes taken for complete disintegration of the tablet with no palatable mass remaining in the apparatus was measured. To comply the test all tablets should disintegrate within 15 minutes.
Drug Content:
Units were selected at random and drug content was determined as specified in monograph. The tablet preparation complies with the test, only if each individual content lies between 85 to 115% of the average content 4 .
In Vitro drug release kinetics studies
Kinetic model had described drug dissolution from solid dosage form where the dissolved amount of drug is a function of test time. In order to study the exact mechanism of drug release from the tablets, drug release data was analyzed according to zero orders, first order, Higuchi square root, korsmeyer peppas model.
RESULT AND DISCUSSION
Compatibility study by IR spectroscopy
Figure 2: FTIR Spectrum of Fluoxetine
The FTIR spectra of pure Fluoxetine showed the peaks at wave numbers (cm -1 ) which correspond to the functional groups present in the structure of the drug.
Differential Scanning Calorimetry:-
The powdered sample (3mg) was hermetically sealed in aluminium pans and heated at a constant rate 100C/min, over a temperature range of 30-3000C with nitrogen flow rate of 30ml/min. Thermograms of the samples were obtained using differential scanning Calorimetry (DSC-60, Shimadzu, Japan). Thermal analysis data were recorded with Shimadzu software programs. Indian standard was to calibrate the DSC temperature and enthalpy scale 
Evaluation of Formulation:
The Fluoxetine tablets were prepared by direct compression method. Ingredients were accurately weighed and passed through mesh. The powder blend was studied for rheological characteristics. The uniformly blend of powder was then compressed in a 10 station tablet punching machine using 12 mm flat faced punches 16 .
Before compression powder bed of all formulations were studied for various rheological characteristics bulk density, true density, compressibility index, Hausner's ratio. The results of the studies indicated that the powder bed is easily compressible, and hence can be compressed into a compact mass of tablets. The angle of repose is an indicative parameter of powder Flowability from hopper to die cavity 17 .
A repose angle between 25 0 to 30 0 indicates excellent Flowability of powder bed. In this work, the angle of repose was found to be varying between 22.81 0 and 26.72 0 when glidants were incorporated. These studies indicated that, the powder beds of all formulations are easily flowable.
Evaluation of Pre-compressed parameters:
All formulations were studied for various rheological characteristics bulk density, true density, compressibility index, Hausner's ratio and angle of repose. The results of the studies indicated that the powder is blend is easily compressible. 
Evaluation of Post Compressed Characteristics:
The results of Hardness, Disintegration time, Drug content, Friability, Swelling index, Floating time all are summarized in the table given below: The dissolution studies were carried out for all nine formulations (i.e. F1 to F9) 
In-Vitro Floating duration
Appearance
The developed formulation met all the pre-requisite to become a floating effervescent tablet, swelled and floated instantaneously at the acidic condition of the stomach. 
Drug release kinetics
In the present study, the drug release was analysed to study the kinetic of drug release mechanism. The results showed that the factorial design batches followed zero order and first order model kinetics, Higuchi and Connor's model kinetics and kosemeyer's peppas model kinetics 20, 21, 22 . The selected formulation were wrapped in aluminium foil and stored at 40 ± 2ºC and % RH 75% ± 5% temperature for 3 months. After 3 months the formulation F3were evaluated for the hardness, drug content and in-vitro % drug release. It was observed that there was no significant variation in the physical appearance, average weight, hardness and loss of drying after placing the tablets at various temperature and humidity conditions for a period of 3 months. Also the cumulative % drug release data showed that each of the formulation released a drug amount, within the limits laid down as per the ICH guidelines for stability studies 23 .
In-vitro drug release profile
Higuchi Model
CONCLUSION:
The present study was carried out to develop the effervescent floating drug delivery of fluoxetine using HPMC K4M and Carbopol 934 polymers as the carrier. Fluoxetine is BCS class I drug having high solubility and high permeability.
Its oral bioavailability 55% and biological half-life is also approximately 14hrs. All the above reason are suitable for gastro retentive drug delivery system. After procurement of drug sample it was characterized for identification by FTIR. After identification check compatibility of drug with all excipient. It was found that it is compatible with all excipient there is no change in functional group. Physical property of Fluoxetine tablet i.e. hardness, friability, average weight, thickness also complies with standard reference. Floating lag time of all nine formulation show within one minute total floating time was more than 12 hrs.
which are suitable for sustained release drug delivery system. The batch F3 shows 96.35% release in 12 hrs, so we concluded that rate of drug release increases in acidic environment of stomach. Release kinetic data of all the formulation show that F1-F9 formulation follows Korsmeyer-Peppas model. Stability study was conducted on tablets of batch F3 at 40±2 0 C for 3 months.. From the discussion it was concluded that the Tablets of batch F3 was selected as optimum batch and evaluated for stability study. 
